期刊文献+

慢性乙肝患者外周血HBcAg18-27V/I变异体特异性淋巴细胞分析 被引量:1

Analysis of HBcAg18-27V/I Mutant Specific Cytotoxic T Lymphocytes (CTL)in Peripheral Blood of Patients with Chronic Hepatitis B
暂未订购
导出
摘要 目的分析不同HBcAg18-27V/I变异体特异性淋巴细胞的频数在慢性乙肝患者外周血中的差异。方法收集44例ALT≥2×ULN的慢性乙肝患者外周血淋巴细胞,通过PCR方法分析感染者病毒学背景(HBV基因型、HBcAg18-27V/I、HLA-A2基因型),应用流式细胞仪分别检测HBcAg18-27V-Tetramer(+)CD8(+)和HBcAg18-27I-Tetramer(+)CD8(+)的淋巴细胞频数。结果华南地区慢性乙肝患者主要为HLA-A2基因型(22/44);感染的HBV主要为B基因型(35/44)。其中HBcAg18-27为I变异体的占优势(43/44),在A2阳性组中,HBcAg18-27I-Tetramer(+)CD8(+)的淋巴细胞频数与HBcAg18-27V-Tetramer(+)CD8(+)的淋巴细胞频数(0.41±0.52VS0.28±0.43)比较差异有统计学意义(P<0.001)。结论在HBV基因型B/C为主的地区,应用HBcAg18-27V表位进行细胞免疫学研究而不考虑HBV病毒学背景的结果可能导致一定的偏差。 Objective To analyze the differences between HBcAg18-27V-tetramer specific CTL and HBcAg18- 27I-tetramer specific CTL in peripheral blood of patients with chronic hepatitis B infection. Method Peripheral blood mononuclear cells (PBMC) were collected from 44 patients with chronic hepatitis B infection (ALT≥2×ULN). The HBV and HLA genotyping, and the mutation of HBcAg18-27 were determined by polymerase chain reaction. CD8+ HBcAg18-27V/I specific CTLs were analysed using flow cytometry. Result 22 out of 44 chronic hepatitis B patients had HLA-A2 genotype. The HBV genotype B was the major genotypes (33 out of 44) in these areas. In addition, HBcAg18-27I was the major variant (43/44). For those patients with the HLA-A2 genotype, the frequency of HBcAg18-27I-tetramer specific CTL (0.41+0.52) was significantly higher than the HBcAg18-27V specific CTL (0.28±0.43,P〈0.001). Conclusion In the HBV (genotype B/C) prevalent area, serological analysis of HBcAg18- 27V is not sufficient. Additional virological analysis should also be performed.
出处 《热带医学杂志》 CAS 2008年第2期104-107,共4页 Journal of Tropical Medicine
基金 国家自然科学基金(No.30571662) 国家基金一等博士后资助(No.2004036019)
关键词 肝炎 慢性 乙型 细胞毒性淋巴细胞 变异 表位 chronic hepatitis B epitope genotype mutation
  • 相关文献

参考文献9

  • 1Stober D, Trobonjaca Z, Reimann J, et al. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class Ⅰ-restricted cytotoxic T cells [J]. Eur J Immunol, 2002,32(4):1099-1108.
  • 2邓洪,韩晓燕,陈幼明,张富程,高志良,姚集鲁.全血染色法和分离外周血单个核细胞染色的五聚体技术检测抗原特异性CTL的比较[J].热带医学杂志,2006,6(5):477-479. 被引量:4
  • 3Zeng G, Wang Z, Wen S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China [J]. J Viral Hepat, 2005,12(6):609- 617.
  • 4阎丽,侯金林,郭亚兵,王战会,林裕龙,骆抗先.乙型肝炎病毒基因型S基因PCR-RFLP分型方法的建立[J].中华传染病杂志,2001,19(4):224-228. 被引量:77
  • 5Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP) [J]. Tissue Antigens, 1995,46(5) : 355-367.
  • 6Chisari FV, Ferrari C. Hepatitis B vires immunopathogenesis [J]. Annu Rev Immunol, 1995,13:29-60.
  • 7Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences [J]. N Engl J Med, 2004, 350:1118-1129.
  • 8Bertoletti A, Chisari FV, Penna A, et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein [ J ]. J Virol, 1993,67 (4) : 2376- 2380.
  • 9Bertoletti A, Costanzo A, Chisafi FV, et al. Cytotoxie T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope [J]. J Exp Med, 1994, 180 ( 3 ) : 933-943.

二级参考文献15

  • 1王洪,周吉军,王宇明.MHC-表位肽四聚体技术在病毒性肝炎研究中的应用[J].世界华人消化杂志,2004,12(6):1432-1436. 被引量:7
  • 2病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 3Ding X,Intervirology,2001年,44卷,43页
  • 4Kao J H,Gastroenterology,2000年,118卷,554页
  • 5范金水,中华微生物学和免疫学杂志,1998年,18卷,88页
  • 6中华传染病杂志,1995年,13卷,241页
  • 7CHISARI F V,FERRARI C.Hepatitis B virus immunopathogenesis[J].Ann Rev Immunol,1995,13(1):29-60.
  • 8SHIMADA N,YAMAMOTO K,KURODA M J,et al.HBcAg-specific CD8 T cells play an important role in virus suppression,and acute flare-up is associated with the expansion of activated memory T cells[J].J Clin Immunol,2003,23 (3):223-232.
  • 9GANEM D,PRINCE A M.Hepatitis B virus infectinn-natural history and clinical consequences[J].N Engl J Med,2004,350(11):1118-1129.
  • 10TSAISL,SHEENIS,CHIENRN,etal.Activation of Th1immunity is a common immune mechanism for the successful treatment of hepatitis B and C:tetramer assay and therapeutic implications[J].J Biomed Sci,2003,10 (1):120-135.

共引文献79

同被引文献13

  • 1于乐成,侯金林.人类白细胞抗原限制性乙型肝炎病毒特异性细胞毒性T淋巴细胞表位研究进展[J].中华肝脏病杂志,2005,13(10):797-800. 被引量:10
  • 2Bertoletti A,Gehimg AJ.The immune response during hepatitis B virus infection.J General Virology,2006,87:1439-1449.
  • 3Maini MK,Boni C,Lee CK,et al.The rule of vires-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection.J Exp Med,2000,191:1269.
  • 4Jager E,Nagata Y,Gnjatic S,et al.Monitoring CD8 T cell responses to NY-ESO-1:correlation of humoral and cellular immune responses.Proc mad Aead Sci USA,2000,97:4760-4765.
  • 5Rehermann B,Nascimbeni M.Immunology of hepatitis B vires and hepatitis C virus infections.Nat Rev Immunol,2005,5(3):215-229.
  • 6Jung MC,Hartmann B,Gerlach JT,et al.Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection.Virology,1999,261 (2):165-172.
  • 7Czerkinsky CC,Tarkowski A,Nilsson LA,et al.Reverse enzymelinked immunospot assay(Elispot) for the detection of cells secreting immunoreactive substances.J Immunol Methods,1984,72:489--496.
  • 8Chisari FV,Ferrari C.HepatitisB virus immunopathogenesis.Annu Rev Immunol,1995,13:29-60.
  • 9Bertoletti A,Naoumov NV.Translation of immunological knowledge into better treatments of chronic hepatitis B.J Hepatol,2003,39(1):115-124.
  • 10Rehermann B,Lan D,Hoofnagh JH,et al.Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.J Clin Invest,1996,97(7):1655-1665.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部